Alpern Robert J 4

What Happened

• Robert J. Alpern, a director of AbbVie Inc. (ABBV), was credited with a 35-share award (derivative stock-equivalent units) on March 31, 2026.
• The units are valued at $217.49 each, for a total value of $7,612. This was recorded as an award/acquisition (code A) of derivative securities rather than an open-market purchase.

Key Details

• Transaction date: 2026-03-31; Filing date: 2026-04-02 (filed timely).
• Price per unit: $217.49; Total value: $7,612.
• Shares owned after transaction: Not specified in the Form 4 filing provided.
• Footnotes:
  • F1 — Director fees were credited to stock-equivalent unit accounts under grantor trusts at Abbott and AbbVie; AbbVie account units will be paid in cash generally at age 65 or upon retirement from AbbVie’s board and earn the same return as if invested in AbbVie stock.
  • F2 — Balance includes stock-equivalent units acquired via a dividend reinvestment feature.

Context

• This was an award of stock-equivalent units (derivative interest) credited to a director trust, not an immediate open-market buy or sale of shares; payout is generally in cash at a later date. Such grants are routine compensation for board service and do not, by themselves, indicate the director buying or selling AbbVie stock on the market.